1. Search Result
Search Result
Results for "

| Anticancer

" in MedChemExpress (MCE) Product Catalog:

4280

Inhibitors & Agonists

30

Screening Libraries

9

Fluorescent Dye

43

Biochemical Assay Reagents

77

Peptides

40

Inhibitory Antibodies

933

Natural
Products

85

Isotope-Labeled Compounds

91

Click Chemistry

933

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148906

    Biochemical Assay Reagents Cancer
    Anticancer agent 95 (compound 24) is a quinazolinone compound with anticancer effects .
    Anticancer agent 95
  • HY-163089

    Others Cancer
    Anticancer agent 176 (Compoint 10α) is an anticancer agent. Anticancer agent 176 exhibits excellent in vitro cytotoxic activity against neuroblastoma with an IC50 value of 6.3 μM .
    Anticancer agent 176
  • HY-151121

    Others Cancer
    Anticancer agent 80 (Compound 3c) is an anticancer agent. Anticancer agent 80 exhibits the dark cytotoxicity against T47-D with IC50 of 10.14 µM .
    Anticancer agent 80
  • HY-115962

    Others Cancer
    Anticancer agent 37 (compound 18), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 37 inhibits HePG2 cell growth with an IC50 of 17.2 µg/mL .
    Anticancer agent 37
  • HY-115963

    Others Cancer
    Anticancer agent 38 (compound 19), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC50 of 5.2 µg/mL .
    Anticancer agent 38
  • HY-151888

    Others Cancer
    Anticancer agent 92 (Compound 5f) is an anticancer agent that is nontoxic against noncancerous cells .
    Anticancer agent 92
  • HY-147968

    Others Cancer
    Anticancer agent 74 is a moderate anticancer agent. Anticancer agent 74 has lower selectivity and cytotoxicity than doxorubicin to normal cell .
    Anticancer agent 74
  • HY-163153

    Apoptosis Cancer
    Anticancer agent 184 (Compound 6o) is a novel, effective and low toxic anticancer drug. Anticancer agent 184 induces apoptosis by blocking the S phase .
    Anticancer agent 184
  • HY-155570

    PI3K Apoptosis Caspase PARP Cancer
    Anticancer agent 137 (8q) is a potent PI3k inhibitor. Anticancer agent 137 has broad-spectrum anticancer activity. Anticancer agent 137 induces G2/M cell cycle arrest and apoptosis. Anticancer agent 137 increases cleaved PARP, caspase 3, and 7. Anticancer agent 137 can be used in research of cancer .
    Anticancer agent 137
  • HY-157487

    Others Cancer
    Anticancer agent 185 (compound 9d) is a glycohybrid derivative of pyrazolopyrimidine [1,5-a]. Anticancer agent 185 has good anti-breast cancer activity. Anticancer agent 185 shows good cytotoxic activity against MCF-7 cells with IC50 value of 15.3 μM .
    Anticancer agent 185
  • HY-163558

    Others Cancer
    Anticancer agent 212 (compound 10a) is a potent anticancer agent. Anticancer agent 212 shows cytotoxicity [1]
    Anticancer agent 212
  • HY-154799

    Others Cancer
    Anticancer agent 112 is a potent anti-cancer agent for cancer research, extracted from patent WO2020198567 .
    Anticancer agent 112
  • HY-149061

    Apoptosis Cancer
    Anticancer agent 99 (compound 2p) has good anticancer activity against HepG2 cells, with an IC50 value of 35.9 μM. Anticancer agent 99 can induce apoptosis and has anti-proliferation effect .
    Anticancer agent 99
  • HY-146396

    Others Cancer
    Anticancer agent 51 (compound 3d) is a potent anticancer agent with an Ki of 731.62 nM. Anticancer agent 51 shows anticancer activity. Anticancer agent 51 has the potential for the research of prostate cancer .
    Anticancer agent 51
  • HY-149805

    Apoptosis Cancer
    Anticancer agent 110 is an anticancer agent with in vitro anticancer activity and excellent anti-leukemia potency. Anticancer agent 110 is highly cytotoxic to K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. Anticancer agent 110 causes DNA damage and leads to apoptosis .
    Anticancer agent 110
  • HY-156253

    Others Cancer
    Anticancer agent 166 (compound 3) is an anticancer agent with an excellent inhibition activity against Caco-2 (IC50 = 9.6 nM) .
    Anticancer agent 166
  • HY-128498

    Others Cancer
    Anticancer agent 182 is a cytotoxic flavonoid compound isolated from the root ofMuntingia colabura L. Anticancer agent 182 exhibits anticancer activity .
    Anticancer agent 182
  • HY-147971

    Parasite Topoisomerase Infection Cancer
    Anticancer agent 75 is a potent anticancer agent. Anticancer agent 75 shows cytotoxicity and selectivity in cancer cell lines. Anticancer agent 75 shows cytotoxicity to normal human kidney cell lines is at least 35 times lower than that of the Doxorubicin standard. Anticancer agent 75 shows good activity of antiplasmodial .
    Anticancer agent 75
  • HY-162276

    Reactive Oxygen Species DNA/RNA Synthesis Cancer
    Anticancer agent 188 (compound D43) inhibits DNA synthesis in TNBC cells, leading to cell cycle arrest at the G2/M phase. Anticancer agent 188 has anti-cancer viability by inducing ROS-mediated apoptosis and DNA damage .
    Anticancer agent 188
  • HY-146030

    Others Cancer
    Anticancer agent 46 (compound 2) is a potent anticancer agent. Anticancer agent 46 shows antiproliferative activity with an IC50 of 0.986 µM for MGC803 cells. Anticancer agent 46 has the potential for the research of gastric cancer .
    Anticancer agent 46
  • HY-157047

    Others Cancer
    Anticancer agent 171 (Compound 6a) is an oxime analogue. Anticancer agent 171 has anticancer activity against HCT116 cells with an IC50 value of 3.43 μM. Anticancer agent 171 can be used for the research of cancer .
    Anticancer agent 171
  • HY-163619

    Apoptosis Mitophagy Cancer
    Anticancer agent 227 (compound YNU-1c) is a potent anticancer agent. Anticancer agent 227 shows antiproliferative activity. Anticancer agent 227 induces apoptosis and mitophagy .
    Anticancer agent 227
  • HY-162670

    CDK Cancer
    Anticancer agent 238 (compound 5) is an anticancer agent with a notably strong binding affinity towards the CDK-5 enzyme. Anticancer agent 238 shows a strong efficacy agains HCT116 and MCF7 cells, with IC50 values of 13.46 µM and 16.43 µM, respectively .
    Anticancer agent 238
  • HY-147906

    Apoptosis PARP Cancer
    Anticancer agent 71 (Compound 4b) is a potent anticancer agent and induces apoptosis. Anticancer agent 71 arrests cell cycle at G2/M phase and induces apoptosis through upregulating Bax, Ikb-α and cleaved PARP and downregulating Bcl-2 expression levels. Anticancer agent 71 shows antiproliferative activity .
    Anticancer agent 71
  • HY-161661

    Others Cancer
    Anticancer agent 223 (Compound V-d) is an anticancer agent that triggers cell death through caspase-dependent and caspase-independent mechanisms. Anticancer agent 223 inhibits tumor spheroid formation and resensitizes cisplatin (HY-17394)-resistant A2780 cells to cisplatin (HY-17394) treatment .
    Anticancer agent 223
  • HY-147909

    Potassium Channel Apoptosis Cancer
    Anticancer agent 72 (compound 8c) is a potent inhibitor of K + channel. Anticancer agent 72 induces apoptosis .
    Anticancer agent 72
  • HY-151092

    Apoptosis Cancer
    Anticancer agent 77 (Compound 6c) shows anticancer activity, and can be widely used in synthesis and medicinal chemistry research .
    Anticancer agent 77
  • HY-149388

    Microtubule/Tubulin Cancer
    Anticancer agent 139 (Compound 6h) has potent anticancer activity. Anticancer agent 139 displayed a π–cationic interaction with the residue Lys352 of Tublin. Anticancer agent 139 has good anticancer activity against SNB-19, OVCAR-8, and NCI-H40 with PGIs of 86.61, 85.26, and 75.99, respectively. Anticancer agent 139 also has moderate anticancer activity against HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 with PGIs of 67.55, 65.46, 59.09, 59.02, 57.88, 56.88, 56.53, 56.4, and 51.88 respectively .
    Anticancer agent 139
  • HY-155278

    Others Cancer
    Anticancer agent 162 (compound 1d) is an effective anticancer theranostic agent. Anticancer agent 162 induces oncosis of Hela cells with lipophilicity and cytotoxicity selectivity .
    Anticancer agent 162
  • HY-115960

    Others Cancer
    Anticancer agent 35 (compound 10), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 35 inhibits A549, A431, PACA2 cell growth with IC50s of 18.1 µg/mL, 4.0 µg/mL, 18.9 µg/mL, respectively .
    Anticancer agent 35
  • HY-146063

    Apoptosis Cancer
    Anticancer agent 54 is a potent anticancer agent. Anticancer agent 54 shows antiproliferative activity. Anticancer agent 54 induces apoptosis and cell cycle arrest at G0/G1 phases. Anticancer agent 54 shows anticancer activity depends on DNA intercalation and ROS generation .
    Anticancer agent 54
  • HY-154865

    Lactate Dehydrogenase Cancer
    Anticancer agent 121, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research .
    Anticancer agent 121
  • HY-154866

    Lactate Dehydrogenase Cancer
    Anticancer agent 122, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research .
    Anticancer agent 122
  • HY-162046

    Necroptosis Ferroptosis Cancer
    Anticancer agent 178 (compound C2) is a potent anticancer agent. Anticancer agent 178 inhibits MDA-MB 231 cells proliferation and metabolic activity with IC50s of 1.1 and 4.2 μM. Anticancer agent 178 induces ferroptosis and necroptosis in cells .
    Anticancer agent 178
  • HY-158049

    Apoptosis Ferroptosis Cancer
    Anticancer agent 199 (Compound G-4) induces apoptosis in triple negative breast cancer (TNBC) cells via the mitochondrial pathway through inhibiting EGFR, AKT and MAPK pathways. Anticancer agent 199 also induces Ferroptosis by down-regulating LCN2. Anticancer agent 199 inhibits TNBC cell viability and migration, and induces S phase cell cycle arrest. Anticancer agent 199 is a derivate of cyclin-dependent kinase inhibitor Rocovitine .
    Anticancer agent 199
  • HY-163770

    Proteasome Cancer
    Anticancer agent 233 (compound 5g) is a 3,5-bis(arylmethylene)-4-piperidinone derivative with anticancer activity, with GI50 of 0.25 and 0.23 μM for cervical cancer (HeLa) and colon cancer (HCT116) cell lines, respectively. The chlorine atom on the aromatic ring of Anticancer agent 233 interacts well with the catalytic site of 20S proteasome, inhibiting the activity of 20S proteasome to exert its anticancer effect .
    Anticancer agent 233
  • HY-154861

    Bacterial Apoptosis Necroptosis Cancer
    Anticancer agent 118, a N‑acylated ciprofloxacin derivative, has anti-bacterial and anticancer activities. Anticancer agent 118 shows high activity against Gram-positive strains and antiproliferative activities against prostate PC3 cells. Anticancer agent 118 can be used for antitumor research .
    Anticancer agent 118
  • HY-163076

    Others Others
    Anticancer agent 174 (BA-3) is an anticancer agent. Anticancer agent 174 induces tumor cell apoptosis through the mitochondrial pathway. Anticancer agent 174 inhibits cancer cell proliferation in melanoma mouse xenograft model .
    Anticancer agent 174
  • HY-155339

    Others Cancer
    Anticancer agent 168 (compound d16) is a inhibitor of DNA2. Anticancer agent 168 induces apoptosis and cell-cycle arrest mainly at S-phase, and exhibits anticancer activities and overcomes chemotherapy resistance in mutp53-bearing cancers .
    Anticancer agent 168
  • HY-162453

    Apoptosis MMP Cancer
    Anticancer agent 204 (Compound 6), a cinnamide fluorinated derivative, possesses anticancer activity. Anticancer agent 204 can arrest the cell cycle of HepG2 cells in the G1 phase and induce apoptosis by reducing the level of mitochondrial membrane polarization (MMP) .
    Anticancer agent 204
  • HY-151471

    c-Myc Cancer
    Anticancer agent 84 is an anticancer agent. Anticancer agent 84 represses the transcription of c-MYC by stabilizing the G-quadruplex (G4) structure. Anticancer agent 84 can be used for the research of cancer .
    Anticancer agent 84
  • HY-149092

    TAM Receptor Cancer
    Anticancer agent 109 (compound 6-15) is an inhibitor of the Gas6-Axl axis with anti-cancer activity. Anticancer agent 109 inhibits the expression of Gas6 and Axl, and the expression p-PI3K and p-AKT in cancer cells, leads to G1 phase arrest and promotes cancer cells apoptosis, and inhibits tumor growth significantly in nude mouse tumor bearing models .
    Anticancer agent 109
  • HY-151207

    Apoptosis ADC Cytotoxin Cancer
    Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the antibody–agent conjugate (ADC) T-PBA. T-PBA maintained its mode of target and internalization ability of Trastuzumab .
    Anticancer agent 81
  • HY-163808

    Apoptosis Cancer
    Anticancer agent 237 (compound 13) is a potent anticancer agent. Anticancer agent 237 shows cytotoxicity. Anticancer agent 237 induces apoptosis and cell cycle arrest at the S and G2/M phases .
    Anticancer agent 237
  • HY-143303

    Apoptosis Cancer
    Anticancer agent 32 (compound 2g) is an anticancer agent. Anticancer agent 32 shows anticancer activities, affects cell cycle and induces cell apoptosis. Anticancer agent 32 can be used for the research of cancer .
    Anticancer agent 32
  • HY-146407

    Apoptosis Cancer
    Anticancer agent 53 is a potent anticancer agent. Anticancer agent 53 shows in vitro cytotoxicity. Anticancer agent 53 induces apoptosis and cell cycle arrest in S/G2/M phases. Anticancer agent 53 shows antitumor activity with no apparent toxicity .
    Anticancer agent 53
  • HY-147918

    DNA/RNA Synthesis Cancer
    Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .
    Anticancer agent 73
  • HY-146433

    Apoptosis Cancer
    Anticancer agent 55 is a potent anticancer agent. Anticancer agent 55 shows anticancer activity via reducing the cell viability and cell migration in a dose-dependent manner. Anticancer agent 55 induces apoptosis. Anticancer agent 55 has the potential for the research of prostate cancer and breast cancer .
    Anticancer agent 55
  • HY-158025

    DNA/RNA Synthesis Cancer
    Anticancer agent 198 (compound 18b) is a potent anticancer agent and potential WRN protein inhibitor. Anticancer agent 198 was significantly toxic to K562 cells and WRN-overexpressing PC3 cells .
    Anticancer agent 198
  • HY-161648

    Others Cancer
    Anticancer agent 222 (Compound 19) is an orally active anticancer agent that exhibits significant anticancer activity against Huh7, FOCUS, SNU475, SNU182, HepG2, and Hep3B cells (IC50 = 2.9–9.3 μM) .
    Anticancer agent 222

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: